LLY · 8-K · 20260805PR000077
Product Pipeline Progress - Retatrutide
ELI LILLY & Co · 2026-08-05 · Importance 31 · Surprise 42 · In source text
Lilly reported positive data from three additional Phase 3 retatrutide trials in obesity. The company said the clinical data package is complete to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain. Lilly plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027.
Key facts
- Lilly plans to submit a Biologics License Application to the U.S. FDA for retatrutide in the first quarter of 2027 to support global registrations for obesity, obstructive sleep apnea, and knee osteoarthritis pain. source
- Pipeline highlights included positive data from three additional Phase 3 trials of retatrutide in obesity. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Lilly plans to submit a Biologics License Application to the U.S. FDA for retatrutide in the first quarter of 2027 to support global… |